Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

INDP vs VIVS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

INDP Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–0 Matrix Metrics)

INDP Overall Winner 6-Pillar Tally: INDP 3 – 2 VIVS (1 Tie) Matrix Metrics: INDP 7 – 0 VIVS

As of Nov 19, 2026, Indaptus Therapeutics, Inc. (INDP) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). INDP carries a Unified Composite Score of 48.8/100 (HOLD) at $3.13 (N/M Forward P/E, 0.0% operating margin), whereas VIVS carries 36.8/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin).

  • Technical & Structure Timing Caution: INDP trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 50.7); meanwhile VIVS is in a Breakdown options structure phase (RSI 75.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About INDP vs VIVS
INDP NASDAQ Head-to-Head Winner
Indaptus Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.13
-4.86% 1D
Market Cap $505.4M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.98β · 94% Vol
Unified Composite Score
48.8 / 100 HOLD
Tech 38.0 Fund 46.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (34.3% over 20 days), RSI 51
RSI-14: 50.7 · SMA20: $3.24 · SMA50: $3.07
VIVS NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap $2.4M
TTM Revenue $112,000
Forward P/E N/M
Beta / 30D Vol 0.83β · 480% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 5.0 Fund 38.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 75
RSI-14: 75.1 · SMA20: $0.15 · SMA50: $0.18

6-Pillar Scorecard Institutional Category Breakdown (INDP 3 – 2 VIVS)

Columns: Metric · INDP · VIVS
1. Valuation Multiples VIVS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 9.6x
2. Growth & Scale INDP
Revenue Growth (YoY) +0.0% -51.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $112,000
Market Cap $505.4M $2.4M
3. Profitability & Quality INDP
Gross Margin N/A N/A
Operating Margin 0.0% -10117.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -318.0% -343.1%
4. Balance Sheet & Cash Flow VIVS
Cash Generation (TTM) -$17M -$11M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.45 Book/Sh · -318.0% ROE $1.4M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning INDP
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: INDP (7) vs VIVS (0)
Institutional Metric INDP VIVS Criterion Row Edge
Market Capitalization
Scale
$505.4M $2.4M Larger Scale INDP
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -51.4% Higher Growth INDP
Operating Margin (TTM)
Profitability
0.0% -10117.0% Higher Margin INDP
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-318.0% -343.1% Higher ROE INDP
52-Week Range Position
Momentum
44% ($1–$6) 5% ($0–$3) Stronger Trend INDP
Beta / 30D Volatility
Risk Regime
0.98β · 94% Vol 0.83β · 480% Vol Lower Realized Risk INDP
Unified Institutional Score
Composite Signal
48.8 / 100 (HOLD) 36.8 / 100 (SELL) Higher Composite INDP
Trailing 12M Revenue (USD)
Operating Scale
N/A $112,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 9.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$17M ($1.45 Book/Sh · -318.0% ROE) -$11M EBITDA ($1.4M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VIVS +65.64 pp
INDP: -0.95% · VIVS: +64.69%
3M Horizon INDP +140.72 pp
INDP: +142.64% · VIVS: +1.92%
6M Horizon INDP +273.53 pp
INDP: +195.28% · VIVS: -78.25%
1Y Horizon INDP +122.49 pp
INDP: +35.5% · VIVS: -86.99%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on INDP vs VIVS. Trailing 12-month operating profitability (INDP 0.0% vs VIVS -10117.0%) and valuation multiples (INDP N/M vs VIVS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

INDP ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-318.0% · N/M
VIVS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$112,000
Gross MarginN/A
Op. Margin-10117.0%
ROE / Fwd P/E-343.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
INDP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact INDP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VIVS BREAKDOWN
73d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact VIVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
INDP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $505.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VIVS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.4M market capitalization and -10117.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ INDP vs VIVS Key Questions & Quantitative Answers

As of Nov 19, 2026, Indaptus Therapeutics, Inc. (INDP) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). INDP carries a Unified Composite Score of 48.8/100 (HOLD) at $3.13 (N/M Forward P/E, 0.0% operating margin), whereas VIVS carries 36.8/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin). Technical & Structure Timing Caution: INDP trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 50.7); meanwhile VIVS is in a Breakdown options structure phase (RSI 75.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

INDP leads the Growth & Scale pillar: INDP posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VIVS at -51.4% YoY revenue growth and +0.0% YoY earnings growth on $112,000 TTM revenue (N/A gross margin, -10117.0% operating margin). On trailing 12-month operating scale, INDP generates N/A in USD-normalized revenue versus $112,000 for VIVS. In operating R&D and SG&A reinvestment, INDP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VIVS.

VIVS screens cheaper on headline valuation multiples. INDP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas VIVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against INDP (-318.0% ROE) versus VIVS (-343.1% ROE) capital efficiency.

In options market volatility and institutional positioning, INDP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.98β · 94% Vol realized risk). By comparison, VIVS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.83β · 480% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.